OPKO Health, Inc. is a biopharmaceutical and diagnostics company, which engages in the provision of healthcare services. It operates through the Diagnostics and Pharmaceuticals segments. The ...

For the quarter ended September 2025, OPKO Health (OPK) reported revenue of $151.7 million, down 12.6% over the same period last year. EPS came in at $0.03, compared to $0.03 in the year-ago quarter.

Opko Health ( (OPK)) has provided an update. On June 18, 2026, OPKO Health, Inc. held its 2026 Annual Meeting of Stockholders, where shareholders elected all eleven nominees to the Board of Directors, ...

The weight-loss drug market is surging, with biotech firms racing to corner a share in a sector dominated by Novo Nordisk and Eli Lilly . March 17, 2025 OPKO and Entera partner to develop obesity pill ...

OPKO Health Inc. (NASDAQ:OPK) is one of the most promising penny stocks according to Wall Street analysts. On April 30, OPKO Health amended its agreement with Nicoya Therapeutics to grant OPKO a 15% ...

OPKO Health, Inc. OPK delivered a loss per share of 19 cents in the second quarter of 2025, wider than the year-ago period’s loss of a penny per share and the Zacks Consensus Estimate of a loss of 12 ...

OPKO Health, Inc. OPK is well-poised for growth in the coming quarters, courtesy of its potential in RAYALDEE. The optimism surrounding the stock is backed by RAYALDEE’s performance and strategic ...

OPKO Health, Inc. OPK delivered a loss per share of 10 cents in the first quarter of 2025, narrower than the year-ago period’s loss of 12 cents per share. However, the metric was wider than the Zacks ...